IL33 and asthma: Moreover, in OVA-induced asthma mice, administration of SnPPIX remarkably counteracted EPO-BM-MSCs-imposed inhibition in lung inflammation (Fig. 5D), reduction in total cell count and inflammatory cell count in BALF (Fig. 5E), repression in airway responsiveness (Fig. 5F), as well as downregulation in IL-4, IL-5, IL-13, TSLP and IL-33 secretion levels in mouse BALF (Fig. 5G and H).